The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Bristol-Myers Squibb; Genentech; Ipsen; Novartis
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Genentech; Ipsen; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Genentech; Ipsen; Novartis
Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.
 
Jonathan R. Strosberg
Honoraria - Novartis
Consulting or Advisory Role - Ipsen; Lexicon; Novartis
Speakers' Bureau - Ipsen; Lexicon
Research Funding - Novartis; Pharmacyclics
Travel, Accommodations, Expenses - Advanced Accelerator Applications
 
Nobumasa Mizuno
Honoraria - Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Pharma Valley Center (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Taiho Pharmaceutical
 
Toshihiko Doi
Consulting or Advisory Role - Amgen; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Sumitomo Dainippon; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Enrique Grande
Consulting or Advisory Role - MSD, Pfizer, IPSEN
Research Funding - Pfizer, AstraZeneca, IPSEN (Inst)
 
Jean-Pierre Delord
No Relationships to Disclose
 
Ronnie Shapira-Frommer
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Clovis Oncology
Travel, Accommodations, Expenses - AstraZeneca Spain; BMS Brazil; MSD
 
Emily K. Bergsland
Stock and Other Ownership Interests - More Health (I)
Consulting or Advisory Role - More Health; more health (I); Novartis
Research Funding - lexicon (Inst); Merck; Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Manisha H. Shah
Consulting or Advisory Role - Eisai; Ignyta; Loxo; Novartis
Research Funding - Eisai; Loxo; Merck
 
Marwan Fakih
Honoraria - Sirtex Medical
Consulting or Advisory Role - Amgen; Array BioPharma; Genentech/Roche
Speakers' Bureau - Amgen; Taiho Pharmaceutical
Research Funding - Merck (Inst); Novartis (Inst)
 
Shunji Takahashi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; MSD; Novartis; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Novartis
 
Sarina Anne Piha-Paul
Research Funding - Abbvie (Inst); Aminex (Inst); Aminex (Inst); Bayer (Inst); BlueLink (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); Samumed (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
Bert O'Neil
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Genentech/Roche; Merck
Speakers' Bureau - Celgene
Travel, Accommodations, Expenses - Bayer; Merck KGaA
 
Sajeve Thomas
No Relationships to Disclose
 
Martijn P. Lolkema
Consulting or Advisory Role - Incyte; Johnson & Johnson; Novartis; Sanofi
Research Funding - Astellas Pharma (Inst); Johnson & Johnson (Inst); Merck Sharp & Dohme (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Merck Sharp & Dohme
 
Jiang Dian Wang
Employment - Merck
 
Nageatte Ibrahim
Employment - Merck
Stock and Other Ownership Interests - GlaxoSmithKline; Merck
 
Scott K. Pruitt
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Julien Hadoux
Consulting or Advisory Role - Ipsen
Travel, Accommodations, Expenses - Ipsen